The Shotlee Journal
Expert insights on GLP-1 medications, peptide therapy, and evidence-based approaches to weight management.
Loading articles...
Showing 9 / 1275 articles
GLP-1 weight-loss drugs like Ozempic and Wegovy are changing how people in Connecticut eat, boosting demand for protein-rich foods to combat muscle loss. Nutrition experts and restaurateurs note shifts toward balanced meals and smaller portions. A clinical epidemiologist reveals how these drugs suppress appetite and delay gastric emptying for significant weight reduction.
The FDA's Commissioner's National Priority Voucher program aims to approve drugs in as little as one month, including anti-obesity medications. Staff and experts raise alarms over skipped steps, legal risks, and safety issues, like patient deaths in trials. Traditional six-to-10-month reviews ensure rigorous safety checks for GLP-1 drugs.
Retired NFL star Tom Brady has taken on the role of Chief Wellness Officer at eMed, a digital health company specializing in GLP-1 medications such as Wegovy and Zepbound. These popular weight-loss drugs offer game-changing results when paired with clinical guidance. Brady's move highlights the growing intersection of sports fame and evidence-based weight management.
GLP-1 medications are quietly revolutionizing grocery shopping by reducing appetite and shifting preferences toward high-protein, high-fiber foods. About 12% of North American adults now use these drugs, with numbers set to rise fast. Learn how this affects what we eat and agriculture's future.
Nearly 85% of GLP-1 users hit a weight loss plateau, but experts say simple tweaks can restart progress. From optimizing doses to boosting protein and walking after meals, discover how to turbocharge Ozempic, Wegovy, or Mounjaro. Avoid quitting—stopping leads to rapid regain, per Oxford research.
Semaglutide injections like Ozempic and Wegovy offer weekly dosing for better adherence than daily pills like Rybelsus, especially for complex regimens or travel. A 2021 JAMA study confirms higher compliance with injections. Tailor your GLP-1 choice to individual needs for optimal results.
Novo Nordisk recalled Wegovy pens after FDA inspectors found hair particles in prefilled syringes. Gold Star Distribution issued a broad recall due to rodent feces and droppings in storage. These Class II recalls highlight contamination risks in GLP-1 medications and pharma supply chains.
New Zealand faces the third-highest adult obesity rate in the OECD, prompting Pharmac to seek clinical advice on funding Wegovy. Two applications propose semaglutide for high-BMI patients with cardiovascular risks or comorbidities. Experts argue it could save billions by preventing diseases like Type 2 diabetes.
Conservative commentator Megyn Kelly labeled Oprah Winfrey's attribution of overeating to an 'obesity gene' a cop-out. In discussions around Winfrey's book with Dr. Ania Jastreboff, GLP-1 medications are highlighted for silencing food noise. Kelly argues millions manage food thoughts without obesity through self-discipline.
